| Identification | Back Directory | [Name]
Cytidine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O,4'-C-methylene-, 3'-[2-cyanoethyl bis(1-methylethyl)phosphoramidite] (9CI) | [CAS]
206055-78-9 | [Synonyms]
DMTr-L-C(Bz)-3-CED-phosphoramidite
DMTr-LNA-C(Bz)-3-CED-phosphoramidite
N4-Benzoyl-5’-O-(4,4’-dimethoxytrityl)-2’-O,4’-C-methylene-cytidine?3’-O-[(2-cyanoethyl)?(N,N-diisopropyl)]-phosphoramidite
N4-Benzoyl-5’-O-(4,4’-dimethoxytrityl)-2’-O,4’-C-methylene-cytidine?3’-O-[(2-cyanoethyl)?(N,N-diisopropyl)]-phosphoramidite
N4-Benzoyl-5’-O-(4,4’-dimethoxy trityl)-2’-O,4’-C-methylene-cytidine 3’-O-[(2-cyanoethyl) (N,N-diisopropyl)]-phosphorramidite
Cytidine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O,4'-C-methylene-, 3'-[2-cyanoethyl bis(1-methylethyl)phosphoramidite] (9CI) | [Molecular Formula]
C47H52N5O9P | [MDL Number]
MFCD30475593 | [MOL File]
206055-78-9.mol | [Molecular Weight]
861.93 |
| Hazard Information | Back Directory | [Uses]
DMTr-LNA-C(Bz)-3-CED-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | [References]
[1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
|
| Company Name: |
Pharmalego
|
| Tel: |
18321033991 |
| Website: |
https://cn.pharmalego.com/ |
| Company Name: |
NOVOCOM
|
| Tel: |
0512-67298826 18362736473 |
| Website: |
www.nvcbiotech.com |
|